[Cost-benefit analysis of screening for congenital toxoplasmosis].
A comprehensive cost-benefit analysis of possible screening strategies for congenital toxoplasmosis is necessary as a basis for the decision whether or not screening is efficient and socially desirable. The total costs of the disease in Switzerland were calculated for the year 1990. Direct costs (all diagnostic and therapeutic interventions, including care of handicapped children) and indirect costs (partial and total work losses in the future) were taken into account. Today, the direct costs amount to approx. SFr. 20 mio per year (i.e. approx. SFr. 2.8 mio per million population). The indirect costs were calculated at SFr. 4 mio per year. Moreover, the costs incurred with three possible screening programs (1 test with all pregnant women, with 1, 2 or 5 additional tests, depending on the strategy) were estimated, together with the concomitant cost savings. The financial resources needed for the screenings would amount to SFr. 7 mio-18 mio per year, depending on the strategy chosen. However, the possible savings would be in the range of SFr. 4 mio-12 mio only. The possible savings are, in any case, of the same order of magnitude as the costs for screening. Screening would become cost-efficient if costs for the serological tests could be lowered.
Sagmeister
M
M
Forschungsgruppe für Management im Gesundheitswesen, Hochschule St. Gallen.
Gessner
U
U
Kind
C
C
Horisberger
B
B
D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008403:Mass Screening / Q000191:economics*; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000191:economics*; D013557:Switzerland; D014125:Toxoplasmosis, Congenital / Q000191:economics / Q000517:prevention & control*; D014126:Toxoplasmosis, Ocular / Q000191:economics / Q000517:prevention & control
Kosten-Nutzen-Analyse des Screenings auf kongenitale Toxoplasmose.